Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118851 | 0.90 | PIK3CG (0.52) | PIK3CGPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL1118916 | 0.88 | PIK3CG (0.51) | PIK3CGPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL1118792 | 0.82 | PIK3CB (0.47) | PIK3CGPIK3CAPIK3CBHTR6 | |
| SCHEMBL1959668 | 0.81 | HTR6 (0.36) | PIK3CGHTR6 | |
| SCHEMBL1959987 | 0.81 | PIK3CD (0.59) | PIK3CGPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL1252454 | 0.80 | HTR6 (0.40) | PIK3CAGSK3BHTR6 | |
| SCHEMBL470192 | 0.79 | NR1H2 (0.41) | HTR6 | |
| SCHEMBL15069989 | 0.76 | PIK3CD (0.55) | PIK3CGPIK3C3PIK3CAPIK3CDPIK3CB | |
| SCHEMBL1118888 | 0.75 | PIK3CB (0.56) | PIK3CGPIK3CAPIK3CB | |
| SCHEMBL12450255 | 0.75 | HTR6 (0.45) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507223-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| WO-2011067365-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067365-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | PIK3CG 181/4885PIK3C3 74/4885PIK3CA 64/4885 |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3C3, PIK3CA, PIK3CD | PIK3CG 14/4885PIK3C3 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.